Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
28 janv. 2025 15h49 HE
|
Tevogen Bio Inc
The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial...
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
24 janv. 2025 17h34 HE
|
Tevogen Bio Inc
This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target...
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
23 janv. 2025 19h53 HE
|
Tevogen Bio Inc
WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
26 déc. 2024 12h21 HE
|
Tevogen Bio Inc
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative...
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
23 déc. 2024 09h38 HE
|
Tevogen Bio Inc
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 13h32 HE
|
Tevogen Bio Inc
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
10 déc. 2024 15h13 HE
|
Tevogen Bio Inc
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
05 nov. 2024 16h43 HE
|
Tevogen Bio Inc
Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately 78% of Tevogen Bio's common stock is held by company...
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
23 oct. 2024 08h35 HE
|
Tevogen Bio Inc
WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
22 oct. 2024 14h30 HE
|
Tevogen Bio Inc
WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...